STEVIE (Safety Events In VIsmodEgib), a single-arm, open-label study on the safety of Hedgehog Pathway Inhibitors in advanced basal cell carcinoma Vismodegib: interim analysis of 150 patients

被引：0
|
作者：
Gutzmer, Ralf [1 ]
Leverkues, Martin [2 ,3 ]
Garbe, Claus [4 ]
Herbst, Rudolf [5 ]
Schadendorf, Dirk [6 ]
Kunstfeld, Rainer [7 ]
Hansson, Johan [8 ]
Basset-Seguin, Nicole [9 ]
Page, Damian [10 ]
Mitchell, Lada [10 ]
Hauschild, Axel [11 ]
机构：
[1] Hannover Med Sch, Hannover, Germany
[2] Univ Med Mannheim, Mannheim, Germany
[3] Univ Heidelberg, Med Fak Mannheim, D-6800 Mannheim, Germany
[4] Univ Klin Tubingen, Tubingen, Germany
[5] HELIOS Hauttumorzentrum, Erfurt, Germany
[6] Univ Klinikum Essen, Essen, Germany
[7] Med Univ Wien, Vienna, Austria
[8] Karolinska Univ Spital, Stockholm, Sweden
[9] Hop St Louis, Paris, France
[10] F Hoffmann La Roche & Cie AG, Basel, Switzerland
[11] Univ Klinikum Schleswig Holstein, Kiel, Germany
来源：
JOURNAL DER DEUTSCHEN DERMATOLOGISCHEN GESELLSCHAFT | 2012年 / 10卷 / 09期
关键词：
D O I：
10.1111/j.1610-0387.2012.08008.x
中图分类号：
R75 [皮肤病学与性病学];
学科分类号：
100206 ;
摘要：
引用
收藏
页码：677 / 677
页数：1
相关论文
共 50 条
  • [1] Interim analysis of STEVIE, a single-arm, open-label, multicentre study to evaluate the safety of the hedgehog pathway inhibitor vismodegib in patients with advanced basal cell carcinoma
    Lear, J. T.
    Gore, M.
    Guerrero-Urbano, T.
    Herd, R.
    Plummer, R.
    Basset-Seguin, N.
    Hansson, J.
    Mitchell, L.
    Starnawski, M.
    Hauschild, A.
    Fife, K.
    BRITISH JOURNAL OF DERMATOLOGY, 2013, 169 : 2 - 2
  • [2] Interim analysis of STEVIE, a single-arm, open-label, multicentre study to evaluate the safety of the hedgehog pathway inhibitor vismodegib in patients with advanced basal cell carcinoma
    Lear, J.
    Fife, K.
    Gore, M.
    Guerrero-Urbano, T.
    Herd, R.
    Plummer, R.
    Seguin, N. Basset
    Hansson, J.
    Mitchell, L.
    Starnawski, M.
    Hauschild, A.
    BRITISH JOURNAL OF DERMATOLOGY, 2014, 171 : 3 - 3
  • [3] UK patient cases from the global single-arm, open-label, multicentre STEVIE study of the hedgehog pathway inhibitor vismodegib in patients with advanced basal cell carcinoma
    Lear, J.
    Fife, K.
    Dreno, B.
    Kunstfeld, R.
    Grob, J. -J.
    Mortier, L.
    Ascierto, P. A.
    Licitra, L.
    Dutriaux, C.
    Jouary, T.
    Meyer, N.
    Guillot, B.
    Dummer, R.
    Ernst, D. S.
    Jones, S.
    Basset-Seguin, N.
    Hansson, J.
    Hauschild, A.
    BRITISH JOURNAL OF DERMATOLOGY, 2015, 173 : 3 - 3
  • [4] Updated STEVIE interim analysis of Hedgehog pathway inhibitor, vismodegib, in 300 patients with advanced basal cell carcinoma
    Grob, J. -J
    Kunstfeld, R.
    Dreno, B.
    Jouary, T.
    Mortier, L.
    Ascierto, P.
    Basset-Seguin, N.
    Hansson, J.
    Mitchell, L.
    Starnawski, M.
    Hauschild, A.
    JOURNAL DER DEUTSCHEN DERMATOLOGISCHEN GESELLSCHAFT, 2013, 11 : 107 - 108
  • [5] Vismodegib in patients with advanced basal cell carcinoma: Primary analysis of STEVIE, an international, open-label trial
    Basset-Seguin, N.
    Hauschild, A.
    Kunstfeld, R.
    Grob, J.
    Dreno, B.
    Mortier, L.
    Ascierto, P. A.
    Licitra, L.
    Dutriaux, C.
    Thomas, L.
    Meyer, N.
    Guillot, B.
    Dummer, R.
    Arenberger, P.
    Fife, K.
    Raimundo, A.
    Dika, E.
    Dimier, N.
    Fittipaldo, A.
    Xynos, I.
    Hansson, J.
    EUROPEAN JOURNAL OF CANCER, 2017, 86 : 334 - 348
  • [6] Vismodegib, a Hedgehog pathway inhibitor (HPI), in advanced basal cell carcinoma (aBCC): STEVIE study interim analysis in 300 patients
    Grob, Jean Jacques
    Kunstfeld, Rainer
    Dreno, Brigitte
    Jouary, Thomas
    Mortier, Laurent
    Basset-Seguin, Nicole
    Ascierto, Paolo Antonio
    Hansson, Johan
    Mitchell, Lada
    Starnawski, Michal
    Hauschild, Axel
    JOURNAL OF CLINICAL ONCOLOGY, 2013, 31 (15)
  • [7] Vismodegib in patients with advanced basal cell carcinoma (STEVIE): a pre-planned interim analysis of an international, open-label trial
    Basset-Seguin, Nicole
    Hauschild, Axel
    Grob, Jean-Jacques
    Kunstfeld, Rainer
    Dreno, Brigitte
    Mortier, Laurent
    Ascierto, Paolo A.
    Licitra, Lisa
    Dutriaux, Caroline
    Thomas, Luc
    Jouary, Thomas
    Meyer, Nicolas
    Guillot, Bernard
    Dummer, Reinhard
    Fife, Kate
    Ernst, D. Scott
    Williams, Sarah
    Fittipaldo, Alberto
    Xynos, Ioannis
    Hansson, Johan
    LANCET ONCOLOGY, 2015, 16 (06): : 729 - 736
  • [8] Safety and efficacy of vismodegib and impact of treatment breaks in advanced basal cell carcinoma: Interim analysis of the STEVIE study in 499 patients
    Kuntsfeld, Rainer
    Grob, Jean-Jacques
    Mortier, Laurent
    Ascierto, Paolo Antonio
    Guillot, Bernard
    Williams, Sarah
    Xynos, Ioannis
    Basset-Seguin, Nicole
    Hansson, Johan
    Hauschild, Axel
    JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY, 2016, 74 (05) : AB204 - AB204
  • [9] Vismodegib in patients with advanced basal cell carcinoma (STEVIE): a pre-planned interim analysis of an international, open-label trial (vol 16, pg 729, 2015)
    Basset-Seguin, N.
    Hauschild, A.
    Grob, J. J.
    LANCET ONCOLOGY, 2016, 17 (08): : E321 - E321
  • [10] Efficacy and safety of the hedgehog pathway inhibitor vismodegib in patients with advanced basal cell carcinoma (BCC): ERIVANCE BCC study update
    Sekulic, Aleksandar
    Migden, Michael R.
    Oro, Anthony E.
    Lewis, Karl D.
    Hainsworth, John D.
    Yoo, Simon
    Dirix, Luc
    Hou, Jeannie
    Yue, Huibin
    Hauschild, Axel
    JOURNAL OF CLINICAL ONCOLOGY, 2012, 30 (15)
12345